Vyaire Medical, a joint venture from Becton Dickinson & Co. (NYSE:BDX) and Apax Partners, said today it acquired airway management developer Revolutionary Medical Devices for an undisclosed amount.
Tucson, Ariz.-based Revolutionary Medical Devices’ main product is the SuperNO2VA, a noninvasive nasal positive airway pressure ventilation system designed to treat respiratory insufficiency from collapsed airways during or after sedation or during intubation.
“The acquisition of Revolutionary Medical Devices allows Vyaire to bring another clinically-differentiated airway management solution to the medical device marketplace. RMD’s SuperNO2VA nasal PAP ventilation system enables anesthesiologists to provide oxygen to sedated patients in a more controlled and noninvasive way, and is exactly the type of unique and thoughtfully-designed product we want to bring to our customers,” Vyaire prez & CEO Dave Mowry said in a press release.
The SuperNO2VA system is designed to open the upper airway and maintain patency to allow for appropriate patient ventilation and to reduce respiratory compromise through perioperative hypoxemia, the companies said.
The system can also be used to pre-oxygenate, relieve upper airway obstruction, maintain ventilation and for rescue ventilation and intra-oral procedures, the company said.
Chicago-based Vyaire said it sees the acquisition as “another step towards the company’s stated goal of becoming the global leader in the respiratory care market.”
BD said it finalized the launch of the Vyaire brand last October.
